Journal
THORACIC CANCER
Volume 9, Issue 1, Pages 159-163Publisher
WILEY
DOI: 10.1111/1759-7714.12518
Keywords
KRAS gene mutation; non-small cell lung cancer; ROS1 fusion gene
Categories
Funding
- Science and Technology Planning Project of Zhejiang Province, China [2015C33194]
- Technology Bureau of Jiaxing City, Zhejiang Province, China [2017BY18060]
- Youth Research Foundation of Shaoxing People's Hospital of Zhejiang Province, China [2017A09]
Ask authors/readers for more resources
Lung adenocarcinomas with gene rearrangement in the receptor tyrosine kinase ROS1 have emerged as a rare molecular subtype. Although these lung adenocarcinomas respond to ROS1tyrosine kinase inhibitors, many patients ultimately acquire resistance. ROS1gene rearrangement is generally mutually exclusive with other driver genomic alterations, such as those in EGFR, KRAS, or ALK, thus multiple genomic alterations are extremely rare. Herein, we report a case of a 42-year-old man diagnosed with lung adenocarcinoma positive for a SDC4-ROS1 fusion, who was treated with crizotinib followed by three cycles of chemotherapy. A biopsy acquired after disease progression revealed the original SDC4-ROS1 fusion along with a KRAS point mutation (p.G12D).We reviewed the related literature to determine the frequency of gene mutations in non-small cell lung cancer patients. A better understanding of the molecular biology of non-small cell lung cancer with multiple driver genomic aberrations will assist in determining optimal treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available